Zonagen (ZONA) Reports Fourth Quarter And Year End 2004 Financial Results And Provides An Update On Company's Core Programs
10/19/2005 5:13:10 PM
THE WOODLANDS, Texas--(BUSINESS WIRE)--March 30, 2005--Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA) today provided an update on the status of its two clinical programs, Progenta(TM) and Androxal(TM), as well as reported both fourth quarter and year end financial results for 2004.
Zonagen is aggressively pursuing a U.S. clinical program for both of its drug candidates. A follow-on public offering of common stock that closed on February 1, 2005 brought in net proceeds of $18.1 million to support this effort.
comments powered by